Product Images Zoledronic Acid

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Zoledronic Acid NDC 63323-966 by Fresenius Kabi Usa, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

zoledronic04 - Zoledronic04

zoledronic04 - Zoledronic04

NDC 63323-966-00 is a sterile solution for intravenous infusion. It is a 100mL single-dose vial that should be stored at a temperature between 15-30°C (59-86°F), excluding excursions permitted, as per USP Controlled Room Temperature. The solution contains 5mg/100mL Zoledronic Acid and should not be mixed with alcohol-containing solutions. The pharmacist should dispense the medication with the accompanying coding area to each patient. It is recommended to administer the solution through a separate vented infusion line and not for a time of less than 15 minutes.*

zoledronic05 - Zoledronic05

zoledronic05 - Zoledronic05

This is a package insert for Zoledronic acid, which is a medication used for the treatment of osteoporosis and bone metastasis. It is a sterile solution that is administered through intravenous infusion. Each vial contains 5.33 mg of zoledronic acid monohydrate, equivalent to 5 mg of zoledronic acid and other ingredients. The solution should not be mixed with calcium-containing solutions and should be administered through a separate vented infusion line. The infusion time must not be less than 15 minutes. The solution is stable for 24 hours when refrigerated. The medication guide should be dispensed to each patient.*

zoledronic01 - zoledronic01

zoledronic01 - zoledronic01

zoledronic02 - zoledronic02

zoledronic02 - zoledronic02

zoledronic03 - zoledronic03

zoledronic03 - zoledronic03

This text describes the therapeutic response over time, specifically the normalization of Serum Alkaline Phosphatase (SAF) levels. It indicates that there is data about the change in SAF levels over a period of time, likely due to medical treatment, and the normalization of these levels is being tracked.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.